The Conversation (0)
Affimed Reports Financial Results for Fourth Quarter and Year End 2017
Mar. 20, 2018 09:04AM PST
Pharmaceutical InvestingAffimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today reported financial results for the quarter and year ended December 31, 2017. As quoted in the press release: “Our approach of harnessing the power of innate and adaptive immunity showed its first clinical potential in 2017 …
Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today reported financial results for the quarter and year ended December 31, 2017.
As quoted in the press release:
“Our approach of harnessing the power of innate and adaptive immunity showed its first clinical potential in 2017 and early 2018 with very encouraging data becoming available for AFM13 as monotherapy in Hodgkin and CD30-positve lymphomas as well as for AFM13 in combination with Keytruda in Hodgkin lymphoma,” said Dr. Adi Hoess, CEO of Affimed. “In addition, we were able to hire outstanding executive managers with Leila Alland as CMO and Wolfgang Fischer as COO, who will be instrumental to the further development of our pipeline towards marketed therapies.”
